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Interferon (IFN) treatment of lentivirus-infected cells substantially reduces virus replication in vitro. Although the replication of
both HIV-1 and simian immunodeficiency virus (SIV) is inhibited, IFN blocks the replication of these viruses at different stages of
the viral life cycle. We previously demonstrated that in HIV-1–infected cells, IFN blocks a late step in viral replication, leading to
a decrease in viral protein stability and a deregulation of polyprotein processing. In contrast, in SIV-infected cells, IFN blocks an
early step in viral replication, between virus binding and reverse transcription. Thus, the viral gene products targeted by IFN may
be different for each of these viruses. To attempt to define which viral proteins are targeted by the IFN response, we examined
the effects of IFN on the replication of two SIV/HIV-1 (SHIV) chimeric viruses, SHIV-4(vpu1) and SHIV-4(vpu2) in 174 3 CEM cells.
These viruses were grown from constructs in which the SIVmac239 env, tat, and rev genes have been replaced with those of HIV-1.
The use of SHIV-4(vpu1) allowed us to examine whether vpu, which is unique to HIV-1, might contribute to the differential effects
of IFN on HIV-1 and SIV replication. Surprisingly, we found that IFN inhibited SHIV replication differently than the replication of
either HIV-1 or SIV. IFN treatment of SHIV-infected cells resulted in a decrease in the level of viral RNA expression but had no
apparent effect on the integration of proviral DNA. Nuclear runoff transcription assays indicated that the reduction in SHIV RNA
expression in IFN-treated cells was not due to alterations in RNA polymerase II-mediated transcription, suggesting that IFN may
block SHIV replication by promoting the increased degradation of viral RNA. The presence or absence of the vpu gene did not alter
the effects of IFN on SHIV replication, indicating that Vpu is not responsible for the differential effect of IFN on HIV-1 and SIV
replication. Thus the response of SHIVs to antiviral agents such as IFN may be unique from either HIV-1 or SIV. This may be an
important consideration when using SHIVs to evaluate anti-HIV-1 therapies in animal models of AIDS. © 1998 Academic Press
INTRODUCTION
Infection of rhesus macaques with simian immuno-
deficiency virus (SIV) results in the development of AIDS.
However, this animal model has certain shortcomings
when used to test the efficacy of anti-HIV–1 vaccines or
therapeutics. In particular, there are differences in the viral
genes encoded by these two lentiviruses, and differences
exist in the immune response to the HIV-1 and SIV enve-
lope glycoprotein (Javaherian et al., 1992). Therefore, a va-
riety of chimeric SIV/HIV-1 viruses (SHIVs) have been de-
veloped to more closely emulate HIV-1 disease in an ani-
mal model. These chimeric viruses have been used to
test the efficacy of anti-HIV–1 vaccines and therapeutics
and have also been useful for examining the role of partic-
ular viral gene products in viral replication (Li et al., 1992,
1995; Balzarini et al., 1995, 1997; Lu et al., 1996).
The antiviral effects of interferon (IFN) on primate lentivi-
rus replication has been the focus of considerable study,
and numerous reports have demonstrated that IFN inhibits
the replication of HIV-1 in vitro (reviewed in Pitha, 1994).
Although IFN has been reported to block both early and late
stages of the HIV-1 life cycle (Fernie et al., 1991; Shirazi and
Pitha, 1992; Coccia et al., 1994; Baca-Regen et al., 1995;
Hansen et al., 1995), we have found that IFN inhibits HIV-1
at a late stage of viral replication by decreasing viral protein
stability and disrupting polyprotein processing (Agy et al.,
1995). In contrast, we found that IFN inhibits SIV replication
at an early stage, between attachment and reverse tran-
scription (Taylor et al., 1998). To attempt to define the viral
gene products responsible for this differential inhibition of
viral replication, we examined the effects of IFN on SHIV
chimeric viruses. We show here that IFN inhibited SHIV
RNA expression but had no apparent effect on the integra-
tion of proviral DNA. Thus IFN inhibited SHIV replication
differently than either HIV-1 or SIV. These results suggest
that important differences in viral replication may exist
among HIV-1, SIV, and SHIV chimeric viruses and that such
differences should be taken into consideration when using
SHIVs to model HIV-1 infection.
RESULTS
SHIV protein production is inhibited
in IFN-treated cells
To investigate the mechanism by which IFN differen-
tially inhibits HIV-1 and SIV replication, we examined the
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effects of IFN on the replication of SIV/HIV-1 chimeric
viruses. We reasoned that chimeric viruses might allow
us to identify which viral gene products are targeted by
the IFN response to inhibit HIV-1 and SIV replication. For
these experiments, we used two SHIV chimeras (Fig. 1),
SHIV-4(vpu1) (Li et al., 1995) and SHIV-4(vpu2) (Li et al.,
1992). These viruses were grown from constructs in
which the SIVmac239 tat, rev, and env genes have been
replaced with those of HIV-1 HXBc2. The SHIV-4(vpu1)
virus contains the functional vpu gene of HIV-1 BH10,
whereas SHIV-4(vpu2) has the nonfunctional vpu gene
(due to a missense mutation in the initiation codon) of
HIV-1 HXBc2. The use of these SHIVs therefore allowed
us to examine whether the vpu gene, which is unique to
HIV-1, might contribute to the differential effects of IFN on
HIV-1 and SIV replication.
As an initial analysis, we examined the effects of IFN
on SHIV protein production. To ensure that we were
observing only primary effects of IFN, a synchronous
infection was established by adding virus to mock or
IFN-treated 1743CEM cells at a high multiplicity of in-
fection. Cellular extracts were prepared at day 3 postin-
fection and examined for the presence of viral proteins
by Western blotting using antibody directed against
SHIV-4(vpu2). Extracts from HIV-1- and SIV-infected cells
(Fig. 2, lanes 1 and 2, respectively) were used as controls
to demonstrate the specificity of the SHIV antisera. Sim-
ilar to our earlier findings with both HIV-1 and SIV, we
found that IFN dramatically decreased the level of viral
protein production in SHIV-infected cells (Fig. 2, lanes 4
and 6). This decrease in viral protein production was the
same for both SHIV-4(vpu1) and SHIV-4(vpu2).
Although IFN treatment leads to a decrease in the
level of viral proteins in HIV–1-infected cells, we previ-
ously found that the rate of viral protein synthesis is only
modestly affected (Agy et al., 1995). We therefore exam-
ined the effects of IFN on the efficiency of viral mRNA
translation in SHIV-infected cells to determine whether
the reduction in the level of SHIV protein production was
due to a decrease in the rate of viral protein synthesis.
Mock or IFN-treated cells were pulse-labeled with [35S]-
methionine for 2 h at day 3 postinfection. Cellular ex-
tracts were then prepared and viral proteins immunopre-
cipitated using pooled sera from SHIV-4(vpu2)-infected
macaques. Analysis of the precipitated proteins by SDS-
PAGE revealed a marked reduction in labeled viral pro-
teins in cells treated with IFN (Fig. 3, lanes 2 and 4). Thus
unlike our previous observations in HIV-1 infected cells,
the rate of SHIV protein synthesis was dramatically re-
duced by IFN treatment. Again no difference was ob-
served between SHIV-4(vpu1) and SHIV-4(vpu2).
SHIV RNA expression is reduced in IFN-treated cells
In addition to a decrease in the rate of viral protein
synthesis, the reduction in viral protein production in
response to IFN could also be the result of a reduction in
viral RNA expression. Therefore to examine whether IFN
had an effect on the steady state level of viral RNA,
Northern blot analysis was performed on RNA isolated
FIG. 1. Structure of SHIV-4(vpu2) and SHIV-4(vpu1). Both SHIVs contain the core genes of SIVmac239 and the env, tat, and rev genes of HIV-1 HXBc2.
SHIV-4(vpu2) contains the nonfunctional HIV-1 HXBc2 vpu gene, which lacks the initiation codon. SHIV-4(vpu1) contains the HIV-1 BH10 vpu gene,
which encodes a functional Vpu protein. Figure adapted from (Li et al., 1995).
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from mock or IFN-treated 1743CEM cells at day 3 postin-
fection. We observed that IFN treatment resulted in a
dramatic decrease in the steady state level of viral RNA
in both SHIV-4(vpu1) and SHIV-4(vpu2)-infected cells
(Fig. 4, lanes 2 and 4), similar to the effect of IFN on SIV
RNA expression that we observed previously (Taylor et
al., 1998). Thus the decrease in viral RNA expression in
response to IFN treatment is likely responsible for the
observed decrease in viral protein production. Because
a decline in viral RNA expression may be the result of
increased RNA degradation, a decrease in viral RNA
transcription, or inhibition of an earlier stage of the viral
life cycle, we undertook an examination of the effects of
IFN on specific early stages of SHIV replication.
Reverse transcription of SHIV RNA is not blocked
in IFN-treated cells
Early stages of lentivirus replication include virus bind-
ing, uncoating of viral RNA, reverse transcription, inte-
gration of proviral DNA into the host genome, and tran-
scription of viral RNA by RNA polymerase II (Clements
and Zink, 1996). To examine the effect of IFN on the
reverse transcription of SHIV RNA, low-molecular–
weight DNA was collected from SHIV-infected cells
and analyzed for cytoplasmic viral replicative inter-
mediates by PCR amplification. For these studies,
mock or IFN-treated 174 3 CEM cells were synchro-
nously infected with SHIV-4(vpu1) or SHIV-4(vpu2) and
low-molecular–weight DNA was isolated at 18 h
postinfection. The presence or absence of viral DNA
was assayed by PCR amplification using two alterna-
tive primer sets, which were designed based on the
reverse transcription model of Varmus and Swanstrom
(Varmus and Swanstrom, 1984). An LTR-specific oligo-
nucleotide primer pair, which amplifies sequences
within the first region of viral DNA synthesized, was
used to detect early steps in reverse transcription.
Full-length or nearly completely synthesized viral
DNA was detected using a primer set specific for a
region of the viral gag gene. Surprisingly, we found
that each primer set amplified viral products from the
DNA of both IFN-treated and untreated cells (Fig. 5),
indicating that IFN had no effect on the reverse tran-
scription of viral RNA in either SHIV-4(vpu1) or SHIV-
4(vpu2)-infected cells. This was in marked contrast to
the effect of IFN on SIV replication. We previously
FIG. 2. The steady-state level of SHIV protein production is decreased in IFN-treated cells. Western blot analysis of 174 3 CEM cell extracts
prepared on day 3 postinfection. Cells were treated with IFN and infected with virus at 0.1 TCID50/cell as indicated below each panel. Blots were
probed with pooled anitsera from SHIV-4(vpu2)-infected rhesus macaques. Extracts from HIV-1- and SIV-infected cells served as controls to
demonstrate the specificity of the SHIV antisera (lanes 1 and 2). To control for protein loading, blots were striped and reprobed with a monoclonal
antibody specific for b-actin. The positions of viral proteins are indicated on the right and molecular weight standards are indicated on the left of each
panel. (A) Analysis of extracts from SHIV-4(vpu1)-infected cells. (B) Analysis of extracts from SHIV-4(vpu2)-infected cells.
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found that IFN completely blocked the reverse tran-
scription of SIV RNA in both 174 3 CEM and MT4 cells
(Taylor et al., 1998).
SHIV proviral DNA integration is not blocked
in IFN-treated cells
To determine if the IFN-mediated decline in SHIV RNA
expression was due to inhibition of proviral DNA integra-
tion, high-molecular–weight DNA was isolated from
SHIV-infected cells and analyzed for proviral sequences
by PCR. Again, two alternative primer sets were used for
this analysis, one specific for the viral LTR and another
specific for the viral gag gene. IFN-treated or untreated
1743CEM cells were infected with SHIV-4(vpu1) or SHIV-
4(vpu2) and high-molecular–weight DNA was collected
at 18 h postinfection. Using LTR or gag specific primer
sets, we observed that viral DNA was amplified from
high-molecular–weight DNA from both IFN-treated and
untreated cells (Fig. 6). Again, no difference was ob-
served between SHIV-4(vpu1) and SHIV-4(vpu2). These
data indicate that SHIV DNA was efficiently synthesized
and integrated in IFN-treated cells, suggesting that the
decrease in viral RNA expression in response to IFN
treatment was due to either a decrease in the rate of viral
RNA transcription or to an increase in the degradation of
viral RNA.
Transcription of SHIV RNA is not affected
in IFN-treated cells
To examine whether IFN disrupted RNA polymerase
II-mediated transcription of viral RNA, we used a nuclear
run-off transcription assay. In isolated nuclei, transcripts
that initiated prior to cell lysis can be efficiently elon-
gated and labeled to high specific activity, thereby pro-
viding a measure of the rate of transcription occurring at
the time of cell lysis (Groudine et al., 1981; Greenberg
and Ziff, 1984). To measure transcription rates, nuclei
were isolated from mock or IFN-treated cells at day 3
postinfection. The isolated nuclei were then incubated in
the presence of [a-32P]UTP and the labeled RNA was
purified and hybridized to filters containing viral and
cellular cDNA clones. Using this assay, we found that the
rate of transcription of SHIV-4(vpu1) and SHIV-4(vpu2)
RNA was the same in mock or IFN-treated cells (Fig. 7).
FIG. 3. The rate of SHIV protein synthesis is decreased in IFN-treated cells. Mock or SHIV-infected 174 3 CEM cells were treated with media or
IFN as indicated below each panel. On day 3 postinfection, cells were labeled for 2 h with [35S]methionine, cell extracts prepared, and SHIV proteins
immunoprecipitated using pooled serum from SHIV-4(vpu2)-infected rhesus macaques. Precipitated proteins were resolved by SDS-PAGE and
examined by autoradiography. The positions of viral proteins are indicated on the right and molecular weight standards are indicated on the left of
each panel. (A) SHIV-4(vpu2). (B) SHIV-4(vpu1).
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This result confirms that SHIV DNA was efficiently syn-
thesized and integrated in IFN-treated cells and sug-
gests that the decrease in the steady-state level of SHIV
RNA expression in response to IFN treatment was not
due to a decrease in the rate of transcription, but is most
likely due to the degradation of SHIV RNA.
DISCUSSION
This study was prompted by our observations that IFN
inhibited the replication of HIV-1 and SIV by different
mechanisms (Agy et al., 1995; Taylor et al., 1998). By
studying the effects of IFN on the replication of a chi-
meric virus, we hoped to identify the viral gene products
targeted by the IFN response. Surprisingly, we found that
the SHIVs used in our studies were inhibited by IFN
differently than either HIV-1 or SIV. The results of our
analyses on the effects of IFN on HIV-1, SIV, and SHIV
replication are summarized in Table 1. We previously
found that IFN inhibits HIV-1 replication at a late stage,
leading to a decrease in viral protein stability and a
deregulation of polyprotein processing. In contrast, in
both SIV- and SHIV-infected cells, IFN treatment resulted
in a decrease in viral RNA expression, although the
mechanism responsible for this effect was different for
each virus. In SIV-infected cells, IFN blocks a step be-
tween attachment and the reverse transcription of viral
RNA (Taylor et al., 1998), whereas in SHIV-infected cells,
IFN had no effect on the reverse transcription of SHIV
RNA or the integration of SHIV provirus into chromo-
somal DNA. Indeed, nuclear run-off transcription analy-
sis indicated that IFN had no effect on the rate of tran-
scription of SHIV RNA transcripts, suggesting that IFN
most likely affects SHIV replication by promoting the
degradation of viral RNA. Thus, although IFN inhibited
the replication of each of these lentiviruses by a unique
mechanism, the phenotype of the SHIVs used in our
study more closely resembled that of HIV-1 with the
block to viral replication occurring at a late stage in the
viral life cycle.
A number of intriguing conclusions can be drawn from
our use of these SHIVs to define a specific viral gene
product responsible for the differential effect of IFN on
HIV-1 and SIV replication. First, the presence or absence
of the vpu gene, which is unique to HIV-1, did not affect
SHIV replication in response to IFN treatment. This result
suggests that Vpu, which has been reported to induce
the downregulation of CD4 (Willey et al., 1992a,b) and
facilitate efficient viral maturation and release (Klimkait
FIG. 4. SHIV RNA expression is reduced in IFN-treated cells. Northern blot analysis of total RNA isolated from 174 3 CEM cells on day 3
postinfection. Blots were probed with [32P]dCTP-labeled SHIV DNA probes as described in Materials and Methods. The lower portion of each panel
shows the same blots after stripping and reprobing with a b-actin probe to control for RNA loading. Major viral transcripts are indicated by the arrows
on the right and the position of 18S and 28S rRNA are shown on the left of each panel. (A) Analysis of RNA extracted from SHIV-4(vpu2)-infected cells.
(B) Analysis of RNA extracted from SHIV-4(vpu1)-infected cells.
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et al., 1990), is not responsible for the differential effect of
IFN on HIV-1 and SIV replication. Second, the SIV reverse
transcriptase also does not appear to be a target of the
IFN response because the SIV reverse transcriptase was
present in the SHIVs used for these analyses and re-
verse transcription was not inhibited. This would suggest
that SIV replication, which we previously found to be
inhibited by IFN at a step between binding and reverse
transcription, may be inhibited at viral entry or uncoating.
This possibility is consistent with our observations that
the SHIVs used in this study, which contained the HIV-1
env gene, more closely resembled HIV-1 than SIV in their
response to IFN treatment. The presence of the HIV-1
env gene may have allowed viral replication to proceed
past the IFN-mediated block to viral entry or uncoating
seen in SIV-infected cells. This may imply that the SIV
envelope is a target of the IFN response or that IFN may
affect an aspect of the interaction between the SIV en-
velope and other viral or cellular factors, such as core-
ceptors, that govern viral entry. In this regard, Chackerian
et al. (1997) reported that a complex interaction between
the viral envelope, coreceptor, and another viral gene
product mediates both entry and post-entry steps of virus
replication. The differential effects of IFN on HIV-1 and
SIV replication may therefore be due not only to the env
gene but to other viral proteins that may interact with the
viral envelope.
The IFN response is quite complex, resulting in the
increased expression of more than 30 genes (Sen and
Lengyel, 1992; Sen and Ransohoff, 1993). Several IFN-
induced gene products have known antiviral properties,
including the dsRNA-activated protein kinase (PKR), the
29-59 oligoadenylate synthetase, RNase L, and the Mx
proteins (Staehli, 1990; Hovanessian, 1991; Zhou et al.,
1993; Silverman, 1994; Katze, 1995; Gale and Katze, 1997).
These IFN-induced gene products can disrupt viral gene
expression at multiple levels, including viral mRNA sta-
bility, transcription, and translation. For example, one
possible mechanism by which SHIV RNA may be de-
graded in response to IFN treatment is through the
action of the IFN-induced ribonuclease, RNase L, which
has been demonstrated to have the capacity to inhibit
viral replication by degrading viral RNAs (Zhou et al.,
1993). A question remains, however, as to why SHIV RNA
might be subject to degradation in response to IFN,
whereas HIV-1 RNA is unaffected. It is conceivable that
the physical structure of the chimeric SHIV RNA may
somehow lend itself susceptible to the effects of a ribo-
nuclease such as RNase L. It is unlikely that the reduc-
tion in SHIV RNA expression in response to IFN was due
to a block in the transport of viral RNA from the nucleus
to the cytoplasm. This would have been detected since
Northern blot analysis was performed on RNA samples
containing both nuclear and cytoplasmic RNAs.
Our observations that the IFN response targets differ-
FIG. 5. IFN has no effect on the reverse transcription of viral RNA in
SHIV-infected cells. Low-molecular–weight DNA was extracted from
SHIV-4(vpu2) (A) or SHIV-4(vpu1)-infected cells (B) and analyzed by
PCR using LTR (lanes 1–3) or gag primer sets (lanes 4–6). Cells were
pretreated with media or IFN prior to infection as indicated below each
panel. Amplification of a mitochondrial DNA sequence (lanes 7–9) was
included as an internal PCR standard for amplification of sequences
present in low-molecular–weight DNA. The positions of size standards
are indicated on the left.
FIG. 6. IFN has no effect on the integration of viral DNA in SHIV-
infected cells. High-molecular–weight DNA was extracted from SHIV-
4(vpu2) (A) or SHIV-4(vpu1)-infected cells (B) and analyzed by PCR
using LTR (lanes 1–3) or gag primer sets (lanes 4–6). Cells were
pretreated with media or IFN prior to infection as indicated below each
panel. Amplification of glyceraldehyde-3-phosphate dehydrogenase
(lanes 7–9) was included as an internal PCR standard for amplification
of sequences present in high-molecular–weight DNA. The positions of
size standards are indicated on the left.
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ent steps of the HIV-1, SIV, and SHIV life cycle suggests
that each of these lentiviruses may interact in a unique
fashion with one or more IFN-induced gene products.
This interaction is likely to involve a complex interplay
between viral gene products as well as with cellular
factors. Thus in SHIV chimeras, the usual interplay
among viral proteins is perturbed and unlike either HIV-1
or SIV, resulting in the unique response to IFN observed
in this study. An understanding of the response of these
viruses to the antiviral effects of IFN may therefore pro-
vide clues into differences in HIV-1, SIV, and SHIV repli-
cation, which may be important for a better understand-
ing of the use of both SIV and SHIV as a model for HIV-1
infection and disease. Finally, and importantly, our re-
sults indicate that when examining the efficacy of various
antiviral therapies, SHIVs may not necessarily have the
same phenotype as either HIV or SIV but may respond in
a unique fashion. This may be particularly important
when examining agents such as IFN, which may act on
multiple targets. Therefore a degree of caution is war-
ranted when using SHIVs to evaluate anti–HIV-1 vac-
cines and therapeutics in animal modes of AIDS.
MATERIALS AND METHODS
Cells, virus infection and IFN treatment
All studies were conducted with 1743CEM cells
(Hoxie et al., 1988), which were obtained from the AIDS
Reagent repository and maintained in RPMI 1640 me-
dium containing 10% heat-inactivated fetal bovine serum
and 10 mM HEPES, pH 7.3. This cell line is highly re-
sponsive to IFN and readily infected with HIV-1, SIV, or
SHIV. The chimeric simian/human immunodeficiency vi-
ruses, SHIV-4(vpu1) (Li et al., 1995) and SHIV-4(vpu2) (Li
et al., 1992) were provided by Dr. John Li. The structure of
these SHIVs is depicted in Fig. 1. SHIV stocks were
prepared by collecting culture supernatants from in-
fected 174 3 CEM cells, and the 50% tissue culture
infectious dose (TCID50) was determined by infecting
multiple wells of 174 3 CEM cells (106 cells/well) with
serial 10-fold dilutions of each SHIV stock. The dilution at
which two of four quadruplicate samples exhibited cyto-
pathic effect (10 days post-infection) was used to calcu-
late the TCID50. This data was confirmed by ELISA anal-
ysis of p27 antigen level in culture supernatants (RETRO-
TEK SIV-1 p27 antigen ELISA, Cellular Products Inc.). To
establish a synchronous infection, virus was added at a
multiplicity of 0.1 TCID50/cell, which rapidly resulted in
infection of nearly 100% of the cells as measured by
indirect immunofluorescence. Trypan blue exclusion was
used to monitor cell viability, and all studies were done in
FIG. 7. Transcription of SHIV RNA is not affected in IFN-treated cells.
Nuclear run-off transcription analysis was performed using nuclei iso-
lated from IFN-treated and untreated cells. The in vitro transcription
and purification of 32P-labeled RNA was performed as described in
Materials and Methods. Labeled RNA (;5 3 106 cpm) from SHIV-
4(vpu1) (A) and SHIV-4(vpu2)-infected cells (B) was hybridized to nylon
membranes containing viral (59 SHIV and 39 SHIV) and cellular (actin)
DNA as indicated.
TABLE 1
Effects of Interferon on Specific Steps in HIV-1, SIV, and SHIV Replication
Virus
Attachment to
cell surface
Reverse
transcription Integration
Viral RNA
transcription
Viral RNA
stability
Viral protein
production
HIV-1 No effect No effect No effect No effect No effect Altered processing
SIV No effect Inhibited Inhibited Inhibited Inhibited Inhibited
SHIV No effect No effect No effect No effect Decreased Inhibited
Note. The effects of IFN on specific stages of viral replication are based on the experiments described in this study and in those by Agy et al. (1995)
and Taylor et al. (1998).
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cultures that contained $85% viable cells. For IFN treat-
ment, human lymphoblastoid IFN (Hayashibara Bio-
chemical Laboratories, Inc.) was added at 1000 units/ml
culture 18 h prior to virus infection.
Protein analysis
For Western blot analysis, cells were disrupted in
ice-cold Triton X-100 lysis buffer (Tang et al., 1996). Pro-
teins were then resolved by SDS-PAGE and transferred
to nitrocellulose membranes. Pooled serum from SHIV-
4(vpu-)-infected rhesus macaques (provided by Dr. Mi-
chael Agy) was used to detect viral proteins. Horseradish
peroxidase-conjugated secondary antibodies were de-
tected by enhanced chemiluminescence.
To analyze viral protein synthesis rates, cells were
metabolically labeled as described previously (Agy et al.,
1990, 1991). Briefly, 2 3 106 viable cells were labeled with
[35S]methionine (100 mCi/ml) for 2 h in media lacking cold
methionine. Cells were then disrupted in Triton X-100
lysis buffer, and viral proteins were immunoprecipitated
using pooled serum from SHIV-4(vpu-)-infected rhesus
macaques. Precipitated proteins were resolved by SDS-
PAGE and examined by autoradiography.
RNA isolation and analysis
Total RNA was isolated from cells by the guanidinium
thiocyanate-phenol-chloroform extraction method (Chom-
czynski and Sacchi, 1987). For Northern blot analysis, RNA
(10 mg/lane) was electrophoresed on denaturing 1% aga-
rose gels and transferred to nylon membranes. Plasmids
pVP-1 (containing the 59 portion of SIVmac239) and pVP-33
(containing HIV-1 env, tat, and rev, and SIV nef and 39 LTR)
(Luciw et al., 1995) (provided by Dr. Paul Luciw) were la-
beled with [a-32P]dCTP by random priming and used as
probes for the detection of viral transcripts.
To measure RNA transcription rates, nuclear runoff
transcription assays were performed essentially as de-
scribed previously (Groudine et al., 1981; Greenberg and
Ziff, 1984; Ausubel et al., 1988). At day 3 postinfection,
nuclei from 7 3 107 cells were isolated in Nonidet P-40
lysis buffer and incubated with [a-32P]UTP to label nas-
cent RNA transcripts. The labeled RNA was then precip-
itated with trichloroacetic acid and hybridized to nylon
membranes (;5 3 106 cpm) containing bound viral (5 mg
of pVP-1 and pVP-33) and cellular (5 mg actin) DNA.
DNA isolation and PCR amplification
Low- and high-molecular–weight DNA was prepared
as previously described (Hirt, 1967). For PCR amplifica-
tion, 100 ng of DNA template was subjected to 35 rounds
of amplification in a reaction volume of 25 ml. Two alter-
native primer sets were used to detect SHIV DNA, a set
specific for the viral LTR (sense, 59-CTACACTTATGAGG-
CATATG-39; antisense, 59-AAAGCAGAAAGGGTCCTAAC-
39; amplified product, 496 bp), and a set specific for the
SIV gag gene (sense, 59-CTGTTGGAGAACAAAGAAGG-
39; antisense, 59-TGGTGCTGTTGGTCTACTTG-39; ampli-
fied product, 215 bp) (Taylor et al., 1998). Primer sets
specific for mitochondrial DNA (sense, 59-GAATGTCTG-
CACAGCCACTTT-39; antisense, 59-ATAGAAAGGCTAGG-
ACCAAAC-39; amplified product, 427 bp) (Stevenson et
al., 1990), and glyceraldehyde-3-phosphate dehydroge-
nase (sense, 59-CACCCATGGCAAATTCCATG-39; antisense,
59-ATGAGCCTACAGCAGAGAAG-39; amplified product,
400 bp) were used as internal PCR standards for low and
high-molecular weight DNA amplification, respectively
(Steinkasserer et al., 1995). PCR products were sepa-
rated on agarose gels and visualized by ethidium bro-
mide staining. Southern blot analysis was used to con-
firm that products amplified using viral DNA-specific
primers contained viral sequences.
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